02.03.20
BryoLogyx Inc., a privately-held, preclinical company developing a new class of drugs to enhance cancer immunotherapies, has appointed David Crockford to the new position of vice president of clinical development and logistics. Mr. Crockford joins BryoLogyx after more than 40 years at pharmaceutical and biotechnology companies, most recently at Neurotrope, where he served as vice president of Regulatory Affairs.
"David brings extensive pharmaceutical development experience, a deep understanding of bryostatin, as well as leadership in regulatory and clinical affairs," said Thomas Loarie, president at BryoLogyx. "BryoLogyx will greatly benefit from his contributions to our team as bryostatin-1 advances towards clinical trials."
At Neurotrope, Mr. Crockford oversaw regulatory affairs as well as manufacturing, all nonclinical toxicology and pharmacology studies and had a key role in Neurotrope’s clinical development planning, implementation and clinical studies. Most recently, he negotiated a CRADA with the NIH and worked with the National Cancer Institute on a potentially enabling approach to improve response to anti-CD22 targeted therapies with bryostatin 1.
"David brings extensive pharmaceutical development experience, a deep understanding of bryostatin, as well as leadership in regulatory and clinical affairs," said Thomas Loarie, president at BryoLogyx. "BryoLogyx will greatly benefit from his contributions to our team as bryostatin-1 advances towards clinical trials."
At Neurotrope, Mr. Crockford oversaw regulatory affairs as well as manufacturing, all nonclinical toxicology and pharmacology studies and had a key role in Neurotrope’s clinical development planning, implementation and clinical studies. Most recently, he negotiated a CRADA with the NIH and worked with the National Cancer Institute on a potentially enabling approach to improve response to anti-CD22 targeted therapies with bryostatin 1.
